Emerging biomarkers of response to ADCs in bladder cancer

Di Jiang, MD, Princess Margaret Hospital, Toronto, Canada, discusses response biomarkers for antibody-drug conjugates (ADCs) in bladder cancer. Since most urothelial cancer cells express nectin-4, target selection is not required for enfortumab vedotin (EV). However, early research has showed nectin-4 amplification and membranous nectin-4 expression as biomarkers associate better with responders. However, disitamab vedotin (DV) and trastuzumab deruxtecan (T-DXd) require selection for HER2+ patients: HER2+ for T-DXd, and both HER2+ and HER3+ for DV. More research into alternative expression of ADC targets in HER2+ patients is required to further inform on treatment. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.